Stocktoria
RenovoRx, Inc. RNXT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-08-17
RenovoRx, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $43,000 | — | — | — |
| Gross profit | $796,000 | $43,000 | — | — | — |
| R&D expense | $6.3M | $6.0M | $5.7M | $4.3M | $3.0M |
| SG&A expense | $7.0M | $5.0M | $5.7M | — | — |
| Operating income | -$12.5M | -$11.0M | -$11.4M | -$9.9M | -$5.7M |
| Income tax | $2,000 | — | — | — | — |
| Net income | -$11.2M | -$8.8M | -$10.2M | -$9.9M | -$6.3M |
| EPS (diluted) | $-0.32 | $-0.40 | $-0.99 | $-1.09 | — |
| Operating cash flow | -$11.0M | -$9.1M | -$10.3M | -$8.8M | -$5.9M |
| Free cash flow | -$11.0M | -$9.1M | — | — | — |
| Cash & equivalents | $7.0M | $7.2M | $1.2M | $4.4M | $15.2M |
| Inventory | $189,000 | $0 | — | — | — |
| Total assets | $8.1M | $8.1M | $1.5M | $7.3M | $16.3M |
| Total liabilities | $2.7M | $3.6M | $4.5M | $1.1M | $938,000 |
| Shareholders' equity | $5.4M | $4.5M | $3.0M | $6.2M | $15.3M |
Source: SEC EDGAR filings · CIK 0001574094 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.